Brief: Olema Oncology Q3 Net Income USD -34.555 Million
12/11/2024 21:01
Nov 12 (Reuters) - Olema Oncology Q3 basic EPS USD -0.6 vs. IBES estimate USD -0.58. * Q3 income from operations USD -37.621 million * Q3 operating expenses USD 37.621 million
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs